Drug Profile
Research programme: anti-VpreB1 antibodies - Pascal Biosciences/University of New Mexico
Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator University of New Mexico
- Developer Pascal Biosciences
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Pre-B cell receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for research development in Precursor-B-cell-lymphoblastic-leukaemia-lymphoma in USA
- 03 Nov 2021 Anti-VpreB1 antibodies is still in early research for Precursor B-cell lymphoblastic leukaemia-lymphoma in the USA (unspecified route) (Pascal Biosciences pipeline, November 2021)
- 03 Nov 2021 Pascal Biosciences files for patent protection for anti-VpreB1 antibodies